Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.…
Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA Trial ...
Hemab Therapeutics Holdings (NASDAQ: COAG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 59 employees.
The shares were at 39.29 USD on 20 November 2026. Its 52-week range is 23.00 USD to 55.42 USD: the price is 29.1% below the high and 70.8% above the low.
Its market capitalisation is 1.84B USD.
Hemab Therapeutics Holdings reports return on equity of 36.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 429.27M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 63.00 USD is 60.3% above the current price. The next earnings report is expected on 11 March 2027.